The study by Ahmed [29] showed Phenotypic changes of MTB-specific T cells are potential surrogate markers for tuberculosis treatment efficacy and can help to discriminate between aTB [profile: CD38(pos), CD27(low)) and latent MTB infection (CD38(neg), CD27(high)], which is consistent with our results. The gene discussed is CD38; the disease is tuberculosis.